Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.

Author:

McDermott David F.1,Lee Jae-Lyun2,Szczylik Cezary3,Donskov Frede4,Malik Jahangeer5,Alekseev Boris Yakovlevich6,Larkin James M. G.7,Matveev Vsevolod Borisovich8,Gafanov Rustem Airatovich9,Tomczak Piotr10,Tykodi Scott S.11,Geertsen Poul F.12,Wiechno Pawel J.13,Shin Sang Joon14,Pouliot Frederic15,Alonso Gordoa Teresa16,Li Wenting17,Perini Rodolfo F.18,Schloss Charles18,Atkins Michael B.19

Affiliation:

1. Beth Israel Deaconess Medical Center, Boston, MA;

2. Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea, Republic of (South);

3. Wojskowy Instytut Medyczny, Warsaw, Poland;

4. Aarhus University Hospital, Aarhus, Denmark;

5. Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom;

6. P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russian Federation;

7. Institute of Cancer Research, London, United Kingdom;

8. N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation;

9. Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation;

10. Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Poznań, Poland;

11. University of Washington Fred Hutchinson Cancer Center, Seattle, WA;

12. Herlev Hospital, University of Copenhagen, Herlev, Denmark;

13. Maria Skłodowska-Curie Memorial Cancer Center, Warsaw, Poland;

14. Yonsei University College of Medicine, Seoul, Korea, Republic of (South);

15. Université Laval, Quebec, QC, Canada;

16. Hospital Universitario Ramón y Cajal, Madrid, Spain;

17. MSD China, Beijing, China;

18. Merck & Co., Inc., Kenilworth, NJ;

19. Georgetown Lombardi Comprehensive Cancer Center, Washington, DC;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 77 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3